

Johns Hopkins Study Affirms Benefit of CancelRx and Leads to Enhancements

A Johns Hopkins Medicine study, funded by a \$42,000 NCPDP Foundation grant, affirms the important function of the CancelRx ePrescribing transaction in decreasing adverse patient events due to medication errors, and will lead to the transaction becoming even more valuable in improving patient safety. CancelRx is an underused transaction in the NCPDP SCRIPT Standard for ePrescribing that enables prescribers to electronically cancel a prescription already submitted to a pharmacy.

Johns Hopkins conducted a pilot implementation of CancelRx in its EHR and pharmacy management system ambulatory setting. The study identified opportunities to enhance proprietary Johns Hopkins workflow decisions and potential enhancements to the CancelRx message that can maximize patient safety and usability. The potential CancelRx enhancements are being addressed by the NCPDP CancelRx sub-task group. They may include additions to the SCRIPT Implementations Recommendations or modifications to CancelRx messaging. Results of the study were published in the peer-reviewed journal, *Applied Clinical Informatics*. As reported in the last issue of this Foundation eNewsletter, a second Johns Hopkins study, co-funded by the NCPDP Foundation, will provide the first evaluation of the clinical impact of CancelRx on erroneous dispensing following intended discontinuation.